QQQ   315.50 (+0.85%)
AAPL   123.04 (+1.69%)
MSFT   233.06 (+1.78%)
FB   262.09 (+2.91%)
GOOGL   2,031.28 (+0.76%)
AMZN   3,075.30 (+0.59%)
TSLA   673.09 (-1.34%)
NVDA   547.68 (+2.89%)
BABA   240.54 (+0.15%)
CGC   32.57 (-1.93%)
GE   12.66 (-0.78%)
MU   91.47 (+3.80%)
NIO   46.27 (-1.15%)
AMD   84.29 (+2.27%)
T   28.04 (-2.06%)
F   11.78 (+0.17%)
ACB   10.70 (-1.11%)
DIS   189.61 (-0.72%)
BA   212.09 (-2.01%)
NFLX   543.51 (-0.58%)
BAC   34.96 (-2.70%)
QQQ   315.50 (+0.85%)
AAPL   123.04 (+1.69%)
MSFT   233.06 (+1.78%)
FB   262.09 (+2.91%)
GOOGL   2,031.28 (+0.76%)
AMZN   3,075.30 (+0.59%)
TSLA   673.09 (-1.34%)
NVDA   547.68 (+2.89%)
BABA   240.54 (+0.15%)
CGC   32.57 (-1.93%)
GE   12.66 (-0.78%)
MU   91.47 (+3.80%)
NIO   46.27 (-1.15%)
AMD   84.29 (+2.27%)
T   28.04 (-2.06%)
F   11.78 (+0.17%)
ACB   10.70 (-1.11%)
DIS   189.61 (-0.72%)
BA   212.09 (-2.01%)
NFLX   543.51 (-0.58%)
BAC   34.96 (-2.70%)
QQQ   315.50 (+0.85%)
AAPL   123.04 (+1.69%)
MSFT   233.06 (+1.78%)
FB   262.09 (+2.91%)
GOOGL   2,031.28 (+0.76%)
AMZN   3,075.30 (+0.59%)
TSLA   673.09 (-1.34%)
NVDA   547.68 (+2.89%)
BABA   240.54 (+0.15%)
CGC   32.57 (-1.93%)
GE   12.66 (-0.78%)
MU   91.47 (+3.80%)
NIO   46.27 (-1.15%)
AMD   84.29 (+2.27%)
T   28.04 (-2.06%)
F   11.78 (+0.17%)
ACB   10.70 (-1.11%)
DIS   189.61 (-0.72%)
BA   212.09 (-2.01%)
NFLX   543.51 (-0.58%)
BAC   34.96 (-2.70%)
QQQ   315.50 (+0.85%)
AAPL   123.04 (+1.69%)
MSFT   233.06 (+1.78%)
FB   262.09 (+2.91%)
GOOGL   2,031.28 (+0.76%)
AMZN   3,075.30 (+0.59%)
TSLA   673.09 (-1.34%)
NVDA   547.68 (+2.89%)
BABA   240.54 (+0.15%)
CGC   32.57 (-1.93%)
GE   12.66 (-0.78%)
MU   91.47 (+3.80%)
NIO   46.27 (-1.15%)
AMD   84.29 (+2.27%)
T   28.04 (-2.06%)
F   11.78 (+0.17%)
ACB   10.70 (-1.11%)
DIS   189.61 (-0.72%)
BA   212.09 (-2.01%)
NFLX   543.51 (-0.58%)
BAC   34.96 (-2.70%)
Log in
NASDAQ:SRGA

Surgalign Stock Forecast, Price & News

$2.49
+0.02 (+0.81 %)
(As of 02/26/2021 02:07 PM ET)
Add
Compare
Today's Range
$2.34
Now: $2.49▼
$2.59
50-Day Range
$1.68
MA: $2.30▼
$3.12
52-Week Range
$1.46
Now: $2.49▼
$4.30
Volume59,410 shs
Average Volume2.46 million shs
Market Capitalization$203.38 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21
Surgalign Holdings, Inc., a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It offers coflex interlaminar stabilization device, an implant for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; SImmetry sacroiliac joint fusion system, which decreases in opioid use, pain, and disability; and Fortilink IBF system with TETRAfuse ?3D technology. The company's implants are used in the fields of orthopedic, spine, sports medicine, plastic surgery, trauma, and other surgical procedures to repair and promote the natural healing of human bone and other human tissues; and to enhance surgical outcomes. It markets its products through its direct distribution force and various OEM relationships to healthcare providers, hospitals, and other healthcare facilities, as well as through a network of independent distributors. The company was founded in 1997 and is headquartered in Deerfield, Illinois.

Headlines

Surgalign Holdings Schedules Fourth Quarter and Full Year 2020 Earnings Call for March 11, 2021 - Yahoo Finance
February 25, 2021 |  finance.yahoo.com
Surgalign Holdings Schedules Fourth Quarter and Full Year 2020 Earnings Call for March 11, 2021 - GlobeNewswire
February 25, 2021 |  globenewswire.com
Surgalign Holdings Schedules Fourth Quarter and Full Year 2020 Earnings Call for March 11, 2021
February 25, 2021 |  finance.yahoo.com
Surgalign Holdings, Inc. Announces Record Date and Annual Meeting Date - Yahoo Finance
February 13, 2021 |  finance.yahoo.com
Surgalign Holdings, Inc. Announces Record Date and Annual Meeting Date - GlobeNewswire
February 12, 2021 |  globenewswire.com
Surgalign Holdings, Inc. Announces Record Date and Annual Meeting Date
February 12, 2021 |  benzinga.com
Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More - Yahoo Finance
February 6, 2021 |  finance.yahoo.com
Surgalign - Benzinga
February 6, 2021 |  benzinga.com
Here's Why AquaBounty Technologies Stock Went Up 14% in January - Nasdaq
February 3, 2021 |  nasdaq.com
Form 4 SURGALIGN HOLDINGS, INC. For: Feb 01 Filed by: STOLPER MARK - StreetInsider.com
February 3, 2021 |  streetinsider.com
Why Surgalign's Stock Is Trading Higher Today - Benzinga
February 3, 2021 |  benzinga.com
Surgalign Holdings Inc (SRGA) President and CEO Terry M. Rich Bought $1.2 million of Shares - Yahoo Finance
February 3, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRGA
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.surgalign.com
Phone877 343 6832
Employees935
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio2.85
Quick Ratio2.32

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$308.38 million
Price / Sales0.66
Cash Flow$0.38 per share
Price / Cash Flow6.50
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($0.16)
Net Income$-211,640,000.00
Net Margins-56.07%
Return on Equity-101.34%
Return on Assets-18.44%

Miscellaneous

Outstanding Shares81,678,000
Market Cap$203.38 million
Next Earnings Date3/11/2021 (Confirmed)
OptionableOptionable

MarketRank™

Overall MarketRank™

1.77 out of 5 stars

Medical Sector

159th out of 1,956 stocks

Surgical Appliances & Supplies Industry

8th out of 40 stocks

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$2.49
+0.02 (+0.81 %)
(As of 02/26/2021 02:07 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRGA News and Ratings via Email

Sign-up to receive the latest news and ratings for SRGA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Surgalign (NASDAQ:SRGA) Frequently Asked Questions

Is Surgalign a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surgalign in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Surgalign stock.
View analyst ratings for Surgalign or view top-rated stocks.

What stocks does MarketBeat like better than Surgalign?

Wall Street analysts have given Surgalign a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Surgalign wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Surgalign's next earnings date?

Surgalign is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Surgalign.

How were Surgalign's earnings last quarter?

Surgalign Holdings, Inc. (NASDAQ:SRGA) released its earnings results on Monday, November, 16th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.19. The business had revenue of $27.93 million for the quarter. Surgalign had a negative trailing twelve-month return on equity of 101.34% and a negative net margin of 56.07%.
View Surgalign's earnings history.

What price target have analysts set for SRGA?

4 analysts have issued 1 year target prices for Surgalign's stock. Their forecasts range from $4.00 to $5.00. On average, they expect Surgalign's share price to reach $4.33 in the next twelve months. This suggests a possible upside of 72.6% from the stock's current price.
View analysts' price targets for Surgalign or view top-rated stocks among Wall Street analysts.

Who are Surgalign's key executives?

Surgalign's management team includes the following people:
  • Mr. Terry M. Rich, Pres, CEO & Director (Age 53, Pay $482.29k)
  • Mr. Jonathon M. Singer, Chief Financial & Operating Officer (Age 57, Pay $710.22k)
  • Mr. Ryan M. Bartolucci, VP & Chief Accounting Officer (Age 40, Pay $588.53k)
  • Mr. Joshua H. DeRienzis, VP, Gen. Counsel & Corp. Sec. (Age 52, Pay $778.83k)
  • Mr. William Scott Durall, Chief Commercial Officer (Age 56, Pay $328.47k)
  • Ms. Molly Poarch, Director of Corp. Communications
  • Mr. Douglas S. Bireley, Exec. VP of Marketing, R&D
  • Ms. Renu Menezes, Exec. VP of HR
  • Mr. John N. Varela, Exec. VP of Global Operations (Age 54)
  • Mr. Enrico Sangiorgio, Exec. VP of International

Who are some of Surgalign's key competitors?

Some companies that are related to Surgalign include Sientra (SIEN), Invacare (IVC), United Health Products (UEEC), Lakeland Industries (LAKE), Milestone Scientific (MLSS), Sanara MedTech (SMTI), Alpha Pro Tech (APT), Nutriband (NTRB), Conformis (CFMS), CollPlant Biotechnologies (CLGN), ReWalk Robotics (RWLK), Myomo (MYO), Predictive Oncology (POAI), Allied Healthcare Products (AHPI) and Bionik Laboratories (BNKL).
View all of SRGA's competitors.

What is Surgalign's stock symbol?

Surgalign trades on the NASDAQ under the ticker symbol "SRGA."

Who are Surgalign's major shareholders?

Surgalign's stock is owned by a number of retail and institutional investors. Top institutional investors include Krensavage Asset Management LLC (7.86%), BlackRock Inc. (6.02%), Dimensional Fund Advisors LP (5.62%), Royce & Associates LP (2.06%), Renaissance Technologies LLC (1.29%) and Dfpg Investments LLC (0.90%). Company insiders that own Surgalign stock include Mark Stolper, Terry M Rich and William Scott Durall.
View institutional ownership trends for Surgalign.

Which institutional investors are selling Surgalign stock?

SRGA stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., GABELLI & Co INVESTMENT ADVISERS INC., Diametric Capital LP, Gabelli Funds LLC, Squarepoint Ops LLC, Renaissance Technologies LLC, Verition Fund Management LLC, and Northern Trust Corp.
View insider buying and selling activity for Surgalign or view top insider-selling stocks.

Which institutional investors are buying Surgalign stock?

SRGA stock was acquired by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, Armistice Capital LLC, Krensavage Asset Management LLC, BlackRock Inc., JPMorgan Chase & Co., Royce & Associates LP, Prelude Capital Management LLC, and Virtu Financial LLC. Company insiders that have bought Surgalign stock in the last two years include Mark Stolper, Terry M Rich, and William Scott Durall.
View insider buying and selling activity for Surgalign or or view top insider-buying stocks.

How do I buy shares of Surgalign?

Shares of SRGA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surgalign's stock price today?

One share of SRGA stock can currently be purchased for approximately $2.51.

How much money does Surgalign make?

Surgalign has a market capitalization of $205.01 million and generates $308.38 million in revenue each year. The company earns $-211,640,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does Surgalign have?

Surgalign employs 935 workers across the globe.

What is Surgalign's official website?

The official website for Surgalign is www.surgalign.com.

Where are Surgalign's headquarters?

Surgalign is headquartered at 520 LAKE COOK ROAD SUITE 315, DEERFIELD IL, 60015.

How can I contact Surgalign?

Surgalign's mailing address is 520 LAKE COOK ROAD SUITE 315, DEERFIELD IL, 60015. The company can be reached via phone at 877 343 6832 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.